Investment Newsletters

Novavax

Novavax: Analyst Cory Kasimov Provides Update From The J.P. Morgan Healthcare Conference

J.P.

Jason Cohen — January 15, 2015, 11:50 AM EDT

We Envision Novavax Building A Strong RSV Franchise With Broad Applicability, Says MLV

In a research note issued this morning, MLV analyst George Zavoico reiterated a Buy rating on Novavax (NASDAQ:NVAX) with a $14 price target, …

Editor Ben Weinberg — October 16, 2014, 10:42 AM EDT

« 1 2 3 4